A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease @ Long Island Clinical Research Associates
Brief description of study
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).
Clinical Study Identifier: s16-01813
ClinicalTrials.gov Identifier: NCT03105128
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
